Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
Propose Pregnancy is a risk factor for severe COVID-19. Treatment with monoclonal antibodies has been shown to decrease the risk of progression to severe COVID-19, but there are few reports on treating pregnant women. Here, we describe the clinical outcome of seven hospitalized pregnant women treated with the casirivimab–imdevimab. Methods/Results Seven unvaccinated pregnant patients hospitalized due to COVID-19 met the monoclonal antibodies treatment criteria applied at our center. After consultations with obstetricians, the decisions to administer casirivimab–imdevimab to halt the progression of COVID-19 were made by two senior infectious diseases specialists. No patient experienced an adverse drug reaction, and only one patient progressed to severe disease. Two patients had a cesarian section performed during hospitalization, both with delivery of healthy babies. Three patients gave birth to healthy babies at a later time point, while two pregnancies are ongoing. Conclusion The hospitalized pregnant patients who received monoclonal antibodies due to COVID-19 had favorable outcomes, but further research is recommended to fully assess safety and efficacy of monoclonal antibody treatment in pregnancy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Infection - 51(2022), 1 vom: 28. Apr., Seite 261-263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Folkman, Rebecca [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022 |
|---|
| doi: |
10.1007/s15010-022-01829-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2133591117 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2133591117 | ||
| 003 | DE-627 | ||
| 005 | 20230506151841.0 | ||
| 007 | tu | ||
| 008 | 230506s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-022-01829-4 |2 doi | |
| 035 | |a (DE-627)OLC2133591117 | ||
| 035 | |a (DE-He213)s15010-022-01829-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 070 |a 610 |q VZ |
| 100 | 1 | |a Folkman, Rebecca |e verfasserin |0 (orcid)0000-0002-3265-010X |4 aut | |
| 245 | 1 | 0 | |a Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022 | ||
| 520 | |a Propose Pregnancy is a risk factor for severe COVID-19. Treatment with monoclonal antibodies has been shown to decrease the risk of progression to severe COVID-19, but there are few reports on treating pregnant women. Here, we describe the clinical outcome of seven hospitalized pregnant women treated with the casirivimab–imdevimab. Methods/Results Seven unvaccinated pregnant patients hospitalized due to COVID-19 met the monoclonal antibodies treatment criteria applied at our center. After consultations with obstetricians, the decisions to administer casirivimab–imdevimab to halt the progression of COVID-19 were made by two senior infectious diseases specialists. No patient experienced an adverse drug reaction, and only one patient progressed to severe disease. Two patients had a cesarian section performed during hospitalization, both with delivery of healthy babies. Three patients gave birth to healthy babies at a later time point, while two pregnancies are ongoing. Conclusion The hospitalized pregnant patients who received monoclonal antibodies due to COVID-19 had favorable outcomes, but further research is recommended to fully assess safety and efficacy of monoclonal antibody treatment in pregnancy. | ||
| 650 | 4 | |a Coronavirus disease | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Pregnancy | |
| 700 | 1 | |a Blennow, Ola |4 aut | |
| 700 | 1 | |a Tovatt, Tuulikki |4 aut | |
| 700 | 1 | |a Pettersson, Karin |4 aut | |
| 700 | 1 | |a Nowak, Piotr |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d Springer Berlin Heidelberg, 1973 |g 51(2022), 1 vom: 28. Apr., Seite 261-263 |w (DE-627)129393010 |w (DE-600)185104-4 |w (DE-576)014777851 |x 0300-8126 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2022 |g number:1 |g day:28 |g month:04 |g pages:261-263 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s15010-022-01829-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2022 |e 1 |b 28 |c 04 |h 261-263 | ||